HIV Monoclonal Antibodies: A New Opportunity to Further Reduce Mother-to-Child HIV Transmission

1. UNAIDS (n.d.) Believe it. Do it—The Global Plan. Available: http://www.unaids.org/believeitdoit/the-global-plan.html. Accessed 8 August 2013.

2. UNAIDS (2013) 2013 progress report on the Global Plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive.

3. RichmanDD, WrinT, LittleSJ, PetropoulosCJ (2003) Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 100: 4144–4149 doi:10.1073/pnas.0630530100

4. RollinsN, CoovadiaHM (2013) Breastfeeding and HIV transmission in the developing world: past, present, future. Curr Opin HIV AIDS 8: 466–472 doi:10.1097/COH.0b013e3283632ba2

5. ChibweshaCJ, GigantiMJ, PuttaN, ChintuN, MulindwaJ, et al. (2011) Optimal time on HAART for prevention of mother-to-child transmission of HIV. J Acquir Immune Defic Syndr 58: 224–228 doi:10.1097/QAI.0b013e318229147e

6. MofensonLM (2010) Antiretroviral drugs to prevent breastfeeding HIV transmission. Antivir Ther 15: 537–553 doi:10.3851/IMP1574

7. NgarinaM, PopenoeR, KilewoC, BiberfeldG, EkstromAM (2013) Reasons for poor adherence to antiretroviral therapy postnatally in HIV-1 infected women treated for their own health: experiences from the Mitra Plus study in Tanzania. BMC Public Health 13: 1–9 doi:10.1186/1471-2458-13-450

8. NachegaJB, UthmanOA, AndersonJ, PeltzerK, WampoldS, et al. (2012) Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a systematic review and meta-analysis. AIDS 26: 2039–2052 doi:10.1097/QAD.0b013e328359590f

9. TillerT, MeffreE, YurasovS, TsuijiM, NussenzweigMC, et al. (2008) Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J Immunol Methods 329: 112–124 doi:10.1016/j.jim.2007.09.017

10. HuangJ, OfekG, LaubL, LouderMK, Doria-RoseNA, et al. (2012) Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491: 406–412 doi:10.1038/nature11544

11. WalkerLM, PhogatSK, Chan-HuiP-Y, WagnerD, PhungP, et al. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285–289 doi:10.1126/science.1178746

12. WalkerLM, HuberM, DooresKJ, FalkowskaE, PejchalR, et al. (2011) Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477: 466–470 doi:10.1038/nature10373

13. WuX, YangZ-Y, LiY, HogerkorpC-M, SchiefWR, et al. (2010) Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329: 856–861 doi:10.1126/science.1187659

14. MascolaJR, HaynesBF (2013) HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol Rev 254: 225–244 doi:10.1111/imr.12075

15. KleinF, MouquetH, DosenovicP, ScheidJF, ScharfL, et al. (2013) Antibodies in HIV-1 vaccine development and therapy. Science 341: 1199–1204 doi:10.1126/science.1241144

16. AdlerSP, NigroG (2013) Prevention of maternal-fetal transmission of cytomegalovirus. Clin Infect Dis Off Publ Infect Dis Soc Am 57 Suppl 4: S189–192 doi:10.1093/cid/cit585

17. Centers for Disease Control (CDC) (1984) Postexposure prophylaxis of hepatitis B. MMWR Morb Mortal Wkly Rep 33: 285–290.

18. Centers for Disease Control and Prevention (CDC) (2012) FDA approval of an extended period for administering VariZIG for postexposure prophylaxis of varicella. MMWR Morb Mortal Wkly Rep 61: 212.

19. The IMpact-RSV Study Group (1998) Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102: 531–537.

20. MigoneT-S, SubramanianGM, ZhongJ, HealeyLM, CoreyA, et al. (2009) Raxibacumab for the treatment of inhalational anthrax. N Engl J Med 361: 135–144 doi:10.1056/NEJMoa0810603

21. Onyango-MakumbiC, OmerSB, MubiruM, MoultonLH, NakabiitoC, et al. (2011) Safety and efficacy of HIV hyperimmune globulin for prevention of mother-to-child HIV transmission in HIV-1-infected pregnant women and their infants in Kampala, Uganda (HIVIGLOB/NVP STUDY). J Acquir Immune Defic Syndr 58: 399–407 doi:10.1097/QAI.0b013e31822f8914

22. StiehmER, LambertJS, MofensonLM, BethelJ, WhitehouseJ, et al. (1999) Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185. J Infect Dis 179: 567–575 doi:10.1086/314637

23. MoldtB, RakaszEG, SchultzN, Chan-HuiP-Y, SwiderekK, et al. (2012) Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc Natl Acad Sci U S A 109: 18921–18925 doi:10.1073/pnas.1214785109

24. Global HIV Vaccine Enterprise (n.d.) HIV prevention trials in infants. Available: http://www.vaccineenterprise.org/content/prevention-trials-infants. Accessed 9 August 2013.

25. ChaselaCS, HudgensMG, JamiesonDJ, KayiraD, HosseinipourMC, et al. (2010) Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med 362: 2271–2281 doi:10.1056/NEJMoa0911486

26. Kesho Bora Study Group, de Vincenzi I (2011) Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 11: 171–180 doi:10.1016/S1473-3099(10)70288-7

27. ThomasTK, MasabaR, BorkowfCB, NdivoR, ZehC, et al. (2011) Triple-antiretroviral prophylaxis to prevent mother-to-child HIV transmission through breastfeeding—the Kisumu Breastfeeding Study, Kenya: a clinical trial. PLoS Med 8: e1001015 doi:10.1371/journal.pmed.1001015

28. WadmanM (2013) HIV trial under scrutiny. Nature 493: 279–280 doi:10.1038/493279a

29. ZalevskyJ, ChamberlainAK, HortonHM, KarkiS, LeungIWL, et al. (2010) Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 28: 157–159 doi:10.1038/nbt.1601

30. ZhouT, GeorgievI, WuX, YangZ-Y, DaiK, et al. (2010) Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329: 811–817 doi:10.1126/science.1192819

31. WyattR, KwongPD, DesjardinsE, SweetRW, RobinsonJ, et al. (1998) The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393: 705–711 doi:10.1038/31514

32. KwongPD, WyattR, RobinsonJ, SweetRW, SodroskiJ, et al. (1998) Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393: 648–659 doi:10.1038/31405

33. ZhouT, XuL, DeyB, HessellAJ, Van RykD, et al. (2007) Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445: 732–737 doi:10.1038/nature05580

34. WHO (2003) Antenatal care in developing countries. Available: http://www.who.int/maternal_child_adolescent/documents/9241590947/en/. Accessed 9 December 2013.

35. Centers for Disease Control and Prevention (CDC) (2011) FastStats: Births and natality. Available: http://www.cdc.gov/nchs/fastats/births.htm. Accessed 9 December 2013.

36. NakamuraKJ, CeriniC, SobreraER, HeathL, SinkalaM, et al. (2013) Coverage of primary mother-to-child HIV transmission isolates by second-generation broadly neutralizing antibodies. AIDS 27: 337–346.